DDInter1814 DDInter1676
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Tioguanine {u} (Compound) treats {v} (Disease) hematologic cancer
Tioguanine {u} (Compound) binds {v} (Gene) IMPDH2
Tioguanine {u} (Compound) causes {v} (Side Effect) Portal hypertension
Tioguanine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Tioguanine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Tioguanine (Compound) resembles Adenine (Compound)
Tioguanine (Compound) treats hematologic cancer (Disease)
Tioguanine (Compound) binds IMPDH2 (Gene)
Tioguanine (Compound) causes Portal hypertension (Side Effect)
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab
Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Tioguanine may lead to a major life threatening interaction when taken with Cladribine
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine